Skip to main content
Sign In
 

Charles A. Dinarello, MD

Professor of Medicine


 

Phone:  303-724-4922
Email:   charles.dinarello@ucdenver.edu
Address: Division of Infectious Diseases
12700 E. 19th Avenue Box B168
Aurora, CO  80045

Charles A. Dinarello is Professor of Medicine and Immunology at the University of Colorado School of Medicine, and Professor of Experimental Medicine at Radboud University in the Netherlands. Professor Dinarello received his medical degree from Yale University and clinical training at Massachusetts General Hospital. From 1971-1977, he was an investigator at the National Institutes of Health in Bethesda. Dr. Dinarello serves on the editorial boards of several scientific journals and has published over 600 original research articles and 250 reviews and book chapters on cytokines, particularly on Interleukin-1, Interleukin-18, and related cytokines. He has trained over 50 investigators, many of whom are recognized experts in their fields. The Institute for Scientific Information listed Dr. Dinarello as the world's 4th most-cited scientist during the 20 years from 1983-2002.
In 1998, Professor Dinarello was elected to the United States National Academy of Sciences, and in 2011, he became a foreign member of the Royal Netherlands Academy of Arts and Sciences. He is a member of the Board of Governors of the Weizmann Institute (Israel) and Ben Gurion University (Israel), former Vice President of the American Society of Clinical Investigation, and was President of the International Cytokine Society. He has received honarary degrees from the University of Marseille (France), the Weizmann Institute of Science (Israel), the University of Frankfurth (Germany), Roosevelt University (USA), Albany Medical College (USA), Radboud University (Netherlands), and Trinity College (Ireland). For his contributions to the field of cytokines and medicine, he received the Squibb Award (USA), Ernst Jung Prize in Medicine (Germany), Chirone Prize (Italian National Academy of Medicine), Carol Nachman Prize (Germany), Sheikh Hamdan bin Rashdid al Madktoum Award (United Arab Emirates), Beering Prize (USA), Albany Prize in Medical Research (USA), Crafoord Prize of the Royal Swedish Academy of Sciences (Sweden), Paul Ehrlich Prize (Germany), Bonfils-Stanton Prize (USA), the Novartiz Prize in Clinical Immunology (Switzerland) and the Bonazinga Award (USA). Dr. Dinarello donates the monies from prizes to the Interleukin Foundation, a charitable foundation which he established in 2009 to support research on cytokines.

  Pub Med Articles

1) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity.
Journal: Proc Natl Acad Sci U S A; 99(21), Oct 15/2002, 13723-8

2) A surface amebic cysteine proteinase inactivates interleukin-18.
Journal: Infect Immun; 71(3), Mar/2003, 1274-80

3) Alveolar type II cells inhibit fibroblast proliferation: role of IL-1alpha.
Journal: Am J Physiol Lung Cell Mol Physiol; 290(2), Feb/2006, L307-16

4) Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone.
Journal: Am J Respir Cell Mol Biol; 30(6), Jun/2004, 830-6

5) Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide.
Journal: Biochem J; 381(Pt 2), Jul 15/2004, 503-10

6) Peripheral blood neutrophil activation patterns are associated with pulmonary inflammatory responses to lipopolysaccharide in humans.
Journal: J Immunol; 176(12), Jun 15/2006, 7753-60

7) Differences in signaling pathways by IL-1beta and IL-18.
Journal: Proc Natl Acad Sci U S A; 101(23), Jun 8/2004, 8815-20

8) Proteinase 3 is an IL-32 binding protein.
Journal: Proc Natl Acad Sci U S A; 103(9), Feb 28/2006, 3316-21

9) Interleukin-32: a cytokine and inducer of TNFalpha.
Journal: Immunity; 22(1), Jan/2005, 131-42

10) IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response.
Journal: Cancer Lett; 229(2), Nov 18/2005, 261-70

11) IL-32, a proinflammatory cytokine in rheumatoid arthritis.
Journal: Proc Natl Acad Sci U S A; 103(9), Feb 28/2006, 3298-303

12) IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.
Journal: Proc Natl Acad Sci U S A; 102(45), Nov 8/2005, 16309-14